Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease

Trends in Pharmacological Sciences

Volumn 24, Issue 12, 2003, Pages 640-647

  Ulbrich, Holger ^a   Eriksson, Einar E ^a   Lindbom, Lennart ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

A 205804; A 304470; ALICAFORSEN; ANTIINFLAMMATORY AGENT; ANTILFA; BIMOSIAMOSE; BIO 1211; BIRT 377; CDP 850; CELL ADHESION MOLECULE; CY 1503; CY 1747; CYLEXIN; DEXAMETHASONE; DREG 200; EFALIZUMAB; EFOMYACINE M; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERLIZUMAB; HU 1124; ICI 747; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; L SELECTIN; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; OC 229648; ODULIMOMAB; PADGEM PROTEIN; ROVELIZUMAB; SELECTIN; SELECTIN ANTAGONIST; SMART; TBC 4746; TR 14035; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CLINICAL TRIAL; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; ENDOTHELIUM; ENDOTHELIUM CELL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; STRUCTURE ANALYSIS;

EID: 0344256483     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.10.004     Document Type: Review

References (62)

1. Witko-Sarsat V., et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80:2000;617-653.
2. Davidson A., Diamond B. Autoimmune diseases. New Engl. J. Med. 345:2001;340-350.
3. Muller W.A. Leukocyte-endothelial cell interactions in the inflammatory response. Lab. Invest. 82:2002;521-533.
4. Carlos T.M., Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood. 84:1994;2068-2101.
5. Ley K. Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants. Immunol. Res. 24:2001;87-95.
6. Ley K. Functions of selectins. Results Probl. Cell Differ. 33:2001;177-200.
7. Vestweber D., Blanks J.E. Mechanisms that regulate the function of the selectins and their ligands. Physiol. Rev. 79:1999;181-213.
8. Sperandio M., et al. Severe impairment of leukocyte rolling in venules of core 2 glucosaminyltransferase-deficient mice. Blood. 97:2001;3812-3819.
9. Foxall C., et al. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J. Cell Biol. 117:1992;895-902.
10. Yang J., et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J. Exp. Med. 190:1999;1769-1782.
11. Eriksson E.E., et al. Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J. Exp. Med. 194:2001;205-218.
12. Sperandio M., et al. P-selectin Glycoprotein Ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J. Exp. Med. 197:2003;1355-1363.
13. Warnock R.A., et al. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J. Exp. Med. 187:1998;205-216.
14. von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343:2000;1020-1034.
15. Xia L., et al. P-selectin glycoprotein ligand-1-deficient mice have impaired leukocyte tethering to E-selectin under flow. J. Clin. Invest. 109:2002;939-950.
16. Takagi J., Springer T.A. Integrin activation and structural rearrangement. Immunol. Rev. 186:2002;141-163.
17. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer. 2:2002;91-100.
18. Hogg N., et al. Mechanisms contributing to the activity of integrins on leukocytes. Immunol. Rev. 186:2002;164-171.
19. Kishimoto T.K., et al. The role of β2 integrins in inflammation. Gallin J.I., Snyderman R. Inflammation: Basic principles and Clinical Correlates. 1999;537-569 Lippincott Williams & Wilkins.
20. Berlin C., et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 80:1995;413-422.
21. Gonzalez-Amaro R., Sanchez-Madrid F. Drugs, inflammation and cell adhesion receptors. Expert Opin. Pharmacother. 2:2001;3-17.
22. Pitzalis C., et al. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann. New York Acad. Sci. 966:2002;108-118.
23. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23:2002;482-486.
24. Kaila N., et al. Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors. Med. Res. Rev. 22:2002;566-601.
25. Slee D., et al. Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with antiinflammatory activity. J. Med. Chem. 44:2001;2094-2107.
26. Lefer D.J. Pharmacology of selectin inhibitors in ischemia/reperfusion states. Annu. Rev. Pharmacol. Toxicol. 40:2000;283-294.
27. Diaz-Ricart M., Bozzo J. rPSGL-1. Drugs Future. 27:2002;346-349.
28. Aydt E., Wolf G. Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma. Pathobiology. 70:2002-3;297-301.
29. Romano S.J., Slee D.H. Targeting selectins for the treatment of respiratory diseases. Curr. Opin. Investig. Drugs. 2:2001;907-913.
30. Schon M.P., et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. 4:2002;366-372. Erratum. Nat. Med. 8, 639.
31. Boehncke W.-H., Schön M.P. Interfering with leukocyte rolling - a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol. Sci. 24:2003;49-52.
32. Bhushan M., et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomised trial. Br. J. Dermatol. 146:2002;824-831.
33. Faxon D., et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J. Am. Coll. Cardiol. 40:2002;1199-1204.
34. Baran K.W., et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 104:2001;2778-2783.
35. Sherman D., et al. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 57:2001;1428-1434.
36. Dedrick R.L. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin. Biol. Ther. 3:2003;85-95.
37. Miller D.H., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl. J. Med. 348:2003;15-23.
38. Ghosh S., et al. Natalizumab for active Crohn's disease. New Engl. J. Med. 348:2003;24-32.
39. van Assche G., Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 8:2002;291-300.
40. Kudlacz E., et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. J. Pharmacol. Exp. Ther. 301:2002;747-752.
41. Harlan J.M., Winn R.K. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit. Care Med. 30:2002;S214-S219.
42. Sims T.N., Dustin M.L. The immunological synapse: integrins take the stage. Immunol. Rev. 186:2002;100-117.
43. Bowen J.D., et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin. Pharmacol. Ther. 64:1998;339-346.
44. Jackson D.Y. Alpha 4 integrin antagonists. Curr. Pharm. Des. 8:2002;1229-1253.
45. Bunting M., et al. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr. Opin. Hematol. 9:2002;30-35.
46. Berton G., Lowell C.A. Integrin signaling in neutrophils and macrophages. Cell. Signal. 11:1999;621-635.
47. Lowe J.B. Glycosylation in the control of selectin counter-receptor structure and function. Immunol. Rev. 186:2002;19-36.
48. Elliott P.J., et al. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. 81:2003;235-245.
49. Onuffer J.J., Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol. Sci. 23:2002;459-467.
50. Kogan T.P., et al. Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269). J. Med. Chem. 41:1998;1099-1111.
51. Yang G., et al. VLA-4 antagonists: Potent inhibitors of lymphocyte migration. Med. Res. Rev. 23:2003;369-392.
52. Pei Z., et al. Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides. J. Med. Chem. 44:2001;2913-2920.
53. Kelly T.A., et al. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J. Immunol. 163:1999;5173-5177.
54. Zoldhelyi P., et al. Inhibition of coronary thrombosis and local inflammation by a noncarbohydrate selectin inhibitor. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H3065-H3075.
55. Mocco J., et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ. Res. 91:2002;907-914.
56. A multicenter, double-blind, placebo-controlled evaluation of Cylexin for reduction of reperfusion injury in infant heart surgery. Circulation. 102:(Suppl. 18):2000;2905.
57. Liu G. Inhibitors of LFA-1/ICAM-1 interaction: from monoclonal antibodies to small molecules. Drugs Future. 26:2001;767-778.
58. Yusuf-Makagiansar H., et al. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22:2002;146-167.
59. Dupree N.J.P., et al. Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. J. Med. Chem. 45:2002;3451-3457.
60. Lin K., et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J. Med. Chem. 42:1999;920-934.
61. Forbes A. Alternative immunomodulators. Eur. J. Gastroenterol. Hepatol. 15:2003;245-248.
62. Zhu D., et al. Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno [2,3-c]pyridines with fine-tuning at C-2 carbamides. J. Med. Chem. 44:2001;3469-3487.